Quality and clinical supply considerations of Paediatric Investigation Plans for IV preparations-A case study with...

Area of Science:

• Pharmaceutical development and regulatory affairs.
• Pediatric clinical pharmacology and drug development.

Background:

• Paediatric Investigation Plans (PIP) are crucial for ensuring adequate data for medicine marketing authorization in children.
• Pharmaceutical development for pediatric populations presents unique regulatory and logistical challenges.

Purpose of the Study:

• To highlight practical considerations and challenges in Paediatric Investigation Plan (PIP) submissions.
• To examine issues encountered during pediatric clinical trials within the pharmaceutical development phase.
• To provide insights from the Clonidine for Sedation of Paediatric Patients in the Intensive Care Unit (CloSed) project for future applicants.

Main Methods:

• Case study analysis of the FP7-funded CloSed project.
• Discussion of practical challenges in formulation development, blinding, randomization, and product labeling/shipment.
• Comparison of clinical trial requirements with marketing authorization requirements for pediatric medicines.

Main Results:

• Identified significant challenges in various aspects of PIP submissions and pediatric clinical trials.
• Highlighted complexities in aligning clinical trial needs with marketing authorization requirements.
• Demonstrated the need for detailed planning and addressing practical hurdles in pediatric drug development.

Conclusions:

• PIP submissions require substantial information and careful consideration of practical challenges.
• The CloSed project offers valuable lessons for optimizing pediatric drug development processes.
• Anticipated benefit for future applicants from understanding these critical considerations and challenges.